Attis Industries, Inc., a technology company, focuses on biomass innovation and healthcare technologies. The company operates in two divisions, Technologies and Innovation. The Technology division focuses on providing patient care services; diagnostic and therapeutic solutions for patients and healthcare providers; and products and services in various areas, including hospital consulting services for laboratory and emergency department, polymerase chain reaction molecular testing, pharmacogenetics testing, and medication therapy management. This division also offers Bright City, a mobile application that enables towns, cities, and municipalities to communicate directly. The Innovation division focuses on producing materials and fuels from renewable sources. The company was formerly known as Meridian Waste Solutions, Inc. and changed its name to Attis Industries, Inc. in April 2018. Attis Industries, Inc. was incorporated in 1993 and is headquartered in Milton, Georgia....
+See More2018-01-08 10:37:00 Monday ET
Spotify considers directly selling its shares to the retail public with no underwriter involvement. The music-streaming company plans a direct list on NYSE
2023-02-07 08:26:00 Tuesday ET
Michel De Vroey delves into the global history of macroeconomic theories from real business cycles to persistent monetary effects. Michel De Vroey (2016)
2025-08-09 11:31:00 Saturday ET
Wharton e-commerce entrepreneurship professor Dr Karl Ulrich explains that many top-notch universities now provide massive open online courses (MOOCs) for m
2019-09-13 10:37:00 Friday ET
China allows its renminbi currency to slide below the key psychologically important threshold of 7-yuan per U.S. dollar. A currency dispute between the U.S.
2023-02-28 10:27:00 Tuesday ET
Basic income reforms can contribute to better health care, public infrastructure, education, technology, and residential protection. Philippe Van Parijs
2019-01-10 17:31:00 Thursday ET
The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be